Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31616404 | 1.00 | TSHR (0.40) | TSHR | |
| SCHEMBL563252 | 1.00 | TSHR (0.40) | TSHR | |
| SCHEMBL30724855 | 1.00 | TSHR (0.40) | TSHR | |
| SCHEMBL1491293 | 1.00 | TSHR (0.40) | TSHR | |
| SCHEMBL2552181 | 1.00 | TSHR (0.40) | TSHR | |
| SCHEMBL18237339 | 1.00 | TSHR (0.40) | TSHR | |
| SCHEMBL18089434 | 1.00 | TSHR (0.40) | TSHR | |
| Hydrochloric Acid SCHEMBL25375836 | 0.97 | TSHR (0.39) | TSHR | |
| SCHEMBL2818899 | 0.95 | — | — | |
| Hydrochloric Acid SCHEMBL25377147 | 0.92 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 141 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025243001-A1 | COVALENT TAG | UNIVERSITY OF DUNDEE (GB) | 2025-11-27 | — | — | WO | disclosed |
| EP-4651903-A1 | M6PR BINDING COMPOUNDS AND CONJUGATES | Lycia Therapeutics, Inc. (US) | 2025-11-26 | — | — | EP | disclosed |
| EP-4651901-A1 | CYCLING LYSOSOMAL TARGETING ANTIBODY CONJUGATES | Lycia Therapeutics, Inc. (US) | 2025-11-26 | — | — | EP | disclosed |
| EP-4651902-A2 | ASGPR BINDING COMPOUNDS AND CONJUGATES | Lycia Therapeutics, Inc. (US) | 2025-11-26 | — | — | EP | disclosed |
| US-20250129082-A1 | N-1 Triazole Substituted Imidazoquinolines, Conjugates Thereof, and Methods | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | 2025-04-24 | — | — | US | disclosed |
| US-20250114461-A1 | CDK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-04-10 | — | — | US | disclosed |
| US-20250101007-A1 | ASGPR CELL SURFACE RECEPTOR BINDING COMPOUNDS AND CONJUGATES | LYCIA THERAPEUTICS, INC. | 2025-03-27 | — | — | US | disclosed |
| US-12258332-B2 | ASGPR cell surface receptor binding compounds and conjugates | LYCIA THERAPEUTICS, INC. (US) | 2025-03-25 | — | — | US | disclosed |
| WO-2025035040-A1 | LYSOSOMAL TARGETING BIFUNCTIONAL MOLECULES FOR DEGRADATION OF MUSCLE-SPECIFIC KINASE AUTOANTIBODIES | LYCIA THERAPEUTICS, INC. (US) | 2025-02-13 | — | — | WO | disclosed |
| US-20240382599-A1 | EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2024-11-21 | — | — | US | disclosed |
| US-8212083-B2 | Use in PEGylation of biologicals; variety of terminal functional groups; made by polymerizing ethylene oxide on initiators such as N-(hydroxyalkyl) imines or N,N-bis(diphenyloxophosphino)-N-hydroxyalkylamines | INTEZYNE TECHNOLOGIES, INC. (US) | 2012-07-03 | — | — | US | disclosed |
| US-20110092668-A1 | AZIDE FUNCTIONALIZED PEPTIDE TARGETING GROUPS | INTEZYNE TECHNOLOGIES, INC. (US) | 2011-04-21 | — | — | US | disclosed |
| US-20110091534-A1 | COMPOSITIONS COMPRISING POLYMERIC MICELLES FOR DRUG DELIVERY | INTEZYNE TECHNOLOGIES, INC. (US) | 2011-04-21 | — | — | US | disclosed |
| US-20100159020-A1 | POLYMERIC MICELLES FOR DRUG DELIVERY | INTEZYNE TECHNOLOGIES, INC. (US) | 2010-06-24 | — | — | US | disclosed |
| US-7638558-B2 | drug loaded micelle of a triblock polymer tert-butylphenylsilylpropene-polyethylene glycol-b-poly(tert-butylaspartic acid-b-polyphenylalanine-copoly( tert-buyltyrosine) has a drug-loaded inner core, a crosslinked outer core, and a hydrophilic shell | INTEZYNE TECHNOLOGIES, INC. (US) | 2009-12-29 | — | — | US | disclosed |
| US-20090234105-A1 | Construction of a Multivalent SCFV Through Alkyne-Azide 1,3-Dipolar Cycloaddition | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-09-17 | — | — | US | disclosed |
| US-20090234105-A1 | Construction of a Multivalent SCFV Through Alkyne-Azide 1,3-Dipolar Cycloaddition | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-09-17 | — | — | US | disclosed |
| US-20090234105-A1 | Construction of a Multivalent SCFV Through Alkyne-Azide 1,3-Dipolar Cycloaddition | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-09-17 | — | — | US | disclosed |
| US-20080188638-A1 | Heterobifunctional poly(ethyleneglycol) containing acid-labile amino protecting groups and uses thereof | INTEZYNE TECHNOLOGIES (US) | 2008-08-07 | — | — | US | disclosed |
| WO-2007112362-A2 | CONSTRUCTION OF A MULTIVALENT SCFV THROUGH ALKYNE-AZIDE 1,3-DIPOLAR CYCLOADDITION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090234105-A1 | Construction of a Multivalent SCFV Through Alkyne-Azide 1,3-Dipolar Cycloaddition | LIG3, LIG1, IGSF11 | TSHR 1028/4885 |
| US-20240382599-A1 | EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE | TBK1, EGFR, CBL | TSHR 3234/4885 |
| US-20080188638-A1 | Heterobifunctional poly(ethyleneglycol) containing acid-labile amino protecting groups and uses thereof | LNPEP, GNE, DNPEP | TSHR 4327/4885 |
| US-20110092668-A1 | AZIDE FUNCTIONALIZED PEPTIDE TARGETING GROUPS | IAPP, NGLY1, MSN | TSHR 822/4885 |
| US-12258332-B2 | ASGPR cell surface receptor binding compounds and conjugates | ASGR1, LAMP2, FCGR2A | TSHR 215/4885 |
| US-20110091534-A1 | COMPOSITIONS COMPRISING POLYMERIC MICELLES FOR DRUG DELIVERY | ABCB4, ABCB11, CLTB | TSHR 3728/4885 |
| US-20250114461-A1 | CDK2 DEGRADERS AND USES THEREOF | CDK2, CDK20, CDK1 | TSHR 3442/4885 |
| US-20250101007-A1 | ASGPR CELL SURFACE RECEPTOR BINDING COMPOUNDS AND CONJUGATES | ASGR1, LAMP2, FCGR2A | TSHR 215/4885 |
| US-20250129082-A1 | N-1 Triazole Substituted Imidazoquinolines, Conjugates Thereof, and Methods | IFNG, IFNAR1, IL2 | TSHR 1515/4885 |
| US-20100159020-A1 | POLYMERIC MICELLES FOR DRUG DELIVERY | ABCB4, CLTB, CD47 | TSHR 3168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.